Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA

Sheldon L. Bolds; Shruthi M.K. Hassan; Catherine R. Caprara; Stephanie Debragga; Kathryn S. Simon; Prachi Karkhanis; Arpita Gandhi; Anand P. Jillella; Vamsi K. Kota

doi:10.4081/hr.2019.7896

Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA

Sheldon L. Bolds, Shruthi M.K. Hassan, Catherine R. Caprara, Stephanie Debragga, Kathryn S. Simon, Prachi Karkhanis, Arpita Gandhi, Anand P. Jillella, Vamsi K. Kota

Pulmonary Disease

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.

Original language	English (US)
Article number	7896
Pages (from-to)	28-29
Number of pages	2
Journal	Hematology Reports
Volume	11
Issue number	2
DOIs	https://doi.org/10.4081/hr.2019.7896
State	Published - 2019

Keywords

Acute promyelocytic leukemia
Early deaths
Supportive care

ASJC Scopus subject areas

Hematology

Access to Document

10.4081/hr.2019.7896

Cite this

@article{c453f41ccfcc4c1eb9a38d7fe7426afe,

title = "Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA",

abstract = "Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.",

keywords = "Acute promyelocytic leukemia, Early deaths, Supportive care",

author = "Bolds, {Sheldon L.} and Hassan, {Shruthi M.K.} and Caprara, {Catherine R.} and Stephanie Debragga and Simon, {Kathryn S.} and Prachi Karkhanis and Arpita Gandhi and Jillella, {Anand P.} and Kota, {Vamsi K.}",

note = "Publisher Copyright: {\textcopyright} S.L. Bolds et al., 2019.",

year = "2019",

doi = "10.4081/hr.2019.7896",

language = "English (US)",

volume = "11",

pages = "28--29",

journal = "Hematology Reports",

issn = "2038-8322",

publisher = "PagePress",

number = "2",

}

TY - JOUR

T1 - Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA

AU - Bolds, Sheldon L.

AU - Hassan, Shruthi M.K.

AU - Caprara, Catherine R.

AU - Debragga, Stephanie

AU - Simon, Kathryn S.

AU - Karkhanis, Prachi

AU - Gandhi, Arpita

AU - Jillella, Anand P.

AU - Kota, Vamsi K.

N1 - Publisher Copyright: © S.L. Bolds et al., 2019.

PY - 2019

Y1 - 2019

N2 - Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.

AB - Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.

KW - Acute promyelocytic leukemia

KW - Early deaths

KW - Supportive care

UR - http://www.scopus.com/inward/record.url?scp=85069669978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069669978&partnerID=8YFLogxK

U2 - 10.4081/hr.2019.7896

DO - 10.4081/hr.2019.7896

M3 - Article

AN - SCOPUS:85069669978

SN - 2038-8322

VL - 11

SP - 28

EP - 29

JO - Hematology Reports

JF - Hematology Reports

IS - 2

M1 - 7896

ER -

Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this